Esaote Unveils Exclusive PAM Technology to Enhance Urological Imaging at EAU 2026

Esaote Unveils Innovative PAM Technology at EAU 2026

Esaote Group, a prominent Italian innovator in medical imaging, is making waves at the 41st Annual Congress of the European Association of Urology (EAU) 2026 in London, presenting its pioneering Prostate Attention Map (PAM) technology. This cutting-edge solution aims to significantly enhance the precision of urological imaging diagnoses and interventions.

Set to impress medical professionals at their booth, Esaote is showcasing the new MyLab™E85 GTS Edition along with the groundbreaking MyLab™C30 GTS imaging system. These innovative products are designed with a strong focus on improving image quality and ensuring effective clinical outcomes in urology, a field that requires accurate and timely diagnostics.

The Prostate Attention Map Technology

At the heart of this innovative approach is the PAM, which provides automatic analysis of multiparametric MRI volumes of the prostate. This function allows for the identification of suspicious regions that are crucial for accurate diagnosis and treatment planning. With the growing importance of early detection in prostate care, PAM stands as a tool that empowers urologists to make more informed decisions during procedures.

Marta Daniel, the product manager for guided therapy solutions at Esaote, emphasizes that this new technology is fully integrated with Esaote's UroFusion software. This integration ensures that healthcare professionals can perform targeted biopsies with greater confidence. By leveraging artificial intelligence, the workflow during biopsies becomes not only optimal but also comparable in duration to standard biopsy procedures. This enhancement significantly boosts accuracy and reliability in clinical practice.

Interactive Learning and Engagement at EAU 2026

During the EAU Congress, Esaote is not just exhibiting. The company is actively engaging in hands-on sessions focused on TP Biopsy and MRI-US Fusion techniques, led by internationally recognized experts. This participation provides attendees with invaluable opportunities to explore the latest advancements in urological imaging and biopsies. It’s a chance for professionals to witness the PAM technology in action and understand its practical applications in real-world scenarios.

Esaote’s involvement in EAU 2026 marks an important milestone in their commitment to providing reliable and clinically relevant imaging solutions. Their offerings aim to enhance clinical excellence, ensuring that urologists have access to advanced tools that support accurate diagnostics and treatment processes. The company's innovative approach is pivotal in transforming the landscape of urological imaging and therapy.

Esaote's Global Presence

Founded and headquartered in Italy, Esaote Group has established itself as a leader in the field of medical imaging, including ultrasounds and MRI technology. As of the end of 2025, Esaote boasted a workforce of approximately 1,300 employees, half of whom are based in Italy. The corporation operates research and production facilities in Genoa and Florence, while extending its reach into over 100 countries worldwide, indicating a robust global footprint.

The introduction of PAM and the launch of the MyLab™E85 GTS and MyLab™C30 GTS systems underscore Esaote’s dedication to innovation and improvement in imaging technology. As the medical field continues to advance, the role of reliable imaging and patient-centered care remains vital, and Esaote is at the forefront of this evolution.